Sanofi (SNY) has sought FDA approval for the expanded use of Dupixent in a sixth potential indication as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease, and a decision is due on June 27, 2024.Dupixent is already approved for the treatment of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis.The drug generated total sales of €2,835 million in the first quarter of 2024, an increase of nearly 25% over the year-ago period. Dupixent is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. Update on May 31, 2024: The FDA decision has been postponed to Sep.27, 2024.SNY closed Wednesday’s trading at $47.57, down 0.77%.